The nasal spray contains a chemical that can inactivate the coronavirus spike protein, which was produced by researchers at the University of Helsinki in Finland. TriSb92, the novel molecule, has been demonstrated to protect against coronavirus infection for at least eight hours in cell cultures and animal trials, even in circumstances of high exposure risk.

In contrast to vaccination protection, TriSb92's action begins very immediately after it is given.

Also read: New COVID variant detected in France, named 'IHU'

"In animal models, nasally delivered TriSb92 provided protection against infection in an exposure condition when all unprotected mice were affected," stated Anna Makela, a varsity postdoctoral researcher. The findings have not yet been subjected to peer review.

The TriSb92 molecule is based on a completely new technology technique for targeting biological agents that was created in Finland. The solution was used in the study to stop the spike protein on the surface of the SARS-CoV-2 virus from working.
"Targeting the TriSb92 molecule's inhibitory impact on a region of the coronavirus spike protein that is common to all variations," Makela stated.

Image showing how TriSb92 works.YLE/wikipedia

TriSb92 was able to stop the spread of SARS, the virus that attacked us in the early 2000s, in model viral tests.

"In other words, we may reasonably expect future varieties of SARS-CoV-2, and possibly even totally new coronaviruses, to be sensitive to it," Makela added.

The chemical might be used as a type of biological defence against coronavirus infection that is sprayed on the mucous membranes in the future if it is given as a nasal spray."

Also read: How Covid infection affects your liver?

These sorts of infection-prevention chemicals, or antiviral medications for that matter, cannot replace vaccinations in safeguarding the population against the coronavirus sickness," stated university Professor Kalle Saksela.

However, there is a pressing need for new ways to improve the protection offered by vaccinations. "TriSb92 may be beneficial to patients whose vaccination protection is limited due to a variety of factors. It may also help fully vaccinated persons when given before any setting with a high chance of exposure, depending on the epidemic condition "Saksela said. (IANS/PR)

(Keywords: TriSb92, SARS-CoV-2 virus, nasal spray, coronavirus infection, infection-prevention chemicals, antiviral medications)